REFERENCES
- Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364 (9431): 369–379.
- Calhoun JH, Manring MM. Adult osteomyelitis. Infect Dis Clin North Am 2005; 19 (4): 765–786.
- I azzarini L, de Lalla F, Mader JT. Long bone osteomyelitis. Curr Infect Dis Rep 2002; 4: 439–445.
- Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical tri- als? Intern J Infect Dis 2005; 9 (3): 127–138.
- Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis 2001; 1 (3): 175–188.
- Trampuz A, Zimmerli W. Antimicrobial agents in or-thopaedic surgery: Prophylaxis and treatment. Drugs 2006; 66 (8): 1089–1105.
- Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive or-ganisms. J Antimicrob Chemother 2004; 53 (4): 669–674.
- Barry AL, Fuchs PC, Brown SD. In vitro activities of dap-tomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001; 45 (6): 1919–1922.
- Fluit AC, Schmitz FJ, Verhoef J, Milatovic D. In vitro activity of daptomycin against Gram-positive European clinical iso-lates with defined resistance determinants. Antimicrob Agents Chemother. 2004; 48 (3): 1007–1011.
- Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphy-lococcus aureus cells. Antimicrob Agents Chemother 2007; 51 (12): 4255–4260.
- Cubicin® (Daptomycin for injection) Prescribing Informa-tion. Lexington, MA: Cubist Pharmaceuticals; July 2006.
- Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clini-cal experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 2007; 120 (10 Suppl 1): S13-S20.
- Lalani T, Boucher HW, Cosgrove SE, Fowler VG, Kanafani ZA, Vigliani GA, et al. Outcomes with daptomycin ver-sus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008; 61 (1): 177–182.
- Falagas ME, Giannopoulou KP, Ntziora F, Papagelopou-los PJ. Daptomycin for the treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents 2007; 30 (3): 202–209.
- Federal Register. Vol.60, No. 40, Wednesday, March 1, 1995, pages 11284-11287.
- Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheterrelated methicillin-resistant Staphylococcus bacteremic isolates embed-ded in biofilm. Antimicrob Agents Chemother 2007; 51 (5): 1656–1660.
- Mader JT, Adams K. Comparative evaluation of dapto-mycin (LY146032) and vancomycin in the treatment of experi-mental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989; 33 (5): 689–692.
- Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karch-mer AW, Rupp ME, et.al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus au-reus. N Engl J Med 2006; 355 (7): 653-665.
- Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI; Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38 (12): 1673–1681.
- Edelsberg J, Berger A, Weber DJ, Mallick R, Kuznik A, Oster G. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008; 29 (2): 160–169.
- Tice AD, Hoaglund PA, Shoultz DA. Outcomes of os-teomyelitis among patients treated with outpatient parenteral an-timicrobial therapy. Am J Med. 2003; 114 (9): 723–728.